Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor Ovarian Reserve Patients

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients

To study the effect of growth hormone as adjuvant treatment on the outcomes of ICSI trials in poor ovarian reserve patients.

Inclusion Criteria:

According to Bologna criteria (((at least two )))of the following features must be present:

1. Advanced maternal age (40years).

2. A previous poor ovarian response with 3 oocytes retrieved after conventional stimulation

3. An abnormal ovarian reserve test (ORT)

   • antral follicle count (AFC)<7 or
   • anti-Müllerian hormone (AMH)<1.1ng/ml.

Exclusion Criteria:

1. Any known contraindications to the approved fertility drugs.
2. Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment)

4- Hydrosalpinx 5- Uterine malformations or abnormal uterine cavity. 6- Basal FSH more than 17 IU. 7- Abnormal karyotyping 8- Partner with severe male factor 9- Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism.